Althera Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALTHERA PHARMS, and what generic alternatives to ALTHERA PHARMS drugs are available?
ALTHERA PHARMS has two approved drugs.
There are two US patents protecting ALTHERA PHARMS drugs.
There are seven patent family members on ALTHERA PHARMS drugs in ten countries and fourteen supplementary protection certificates in eight countries.
Summary for Althera Pharms
| International Patents: | 7 |
| US Patents: | 2 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Althera Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-003 | Mar 23, 2021 | DISCN | Yes | No | 10,376,470 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-004 | Mar 23, 2021 | DISCN | Yes | No | 10,376,470 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-002 | Mar 23, 2021 | DISCN | Yes | No | 10,376,470 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Althera Pharms | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-002 | Apr 26, 2017 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-001 | Mar 23, 2021 | DISCN | Yes | No | 9,763,885 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Althera Pharms | ROSZET | ezetimibe; rosuvastatin calcium | TABLET;ORAL | 213072-002 | Mar 23, 2021 | DISCN | Yes | No | 9,763,885 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Althera Pharms | LYPQOZET | atorvastatin calcium; ezetimibe | TABLET;ORAL | 206084-003 | Apr 26, 2017 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Althera Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 365046 | ⤷ Sign Up |
| Portugal | 2844233 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2013166117 | ⤷ Sign Up |
| Mexico | 2014013241 | ⤷ Sign Up |
| Denmark | 2844233 | ⤷ Sign Up |
| Spain | 2802252 | ⤷ Sign Up |
| Hungary | E052300 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Althera Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0720599 | 300689 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| 0720599 | 92545 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ATORVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ATORVASTATINE SOUS FORME D'ATORVASTATINE CALCIQUE TRIHYDRATEE; FIRST REGISTRATION: 20140910 |
| 0720599 | CR 2014 00050 | Denmark | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
| 0720599 | 122014000088 | Germany | ⤷ Sign Up | PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912 |
| 1003503 | 30/2006 | Austria | ⤷ Sign Up | PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SAEUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN; NAT. REGISTRATION NO/DATE: 1-26271, 1-26273 20060330; FIRST REGISTRATION: FR 369300.9;369301.5; 369302.1;369303.8;369304.4;369305.0; 20050707 |
| 0247633 | 97C0118 | France | ⤷ Sign Up | PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107 |
| 1003503 | 05C0048 | France | ⤷ Sign Up | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
